StageZero Life Sciences Ltd
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers fr… Read more
StageZero Life Sciences Ltd - Asset Resilience Ratio
StageZero Life Sciences Ltd (SZLSF) has an Asset Resilience Ratio of 81.79% as of September 2013. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2012)
This chart shows how StageZero Life Sciences Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down StageZero Life Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.25 Million | 81.79% |
| Total Liquid Assets | $4.25 Million | 81.79% |
Asset Resilience Insights
- Very High Liquidity: StageZero Life Sciences Ltd maintains exceptional liquid asset reserves at 81.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
StageZero Life Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare StageZero Life Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for StageZero Life Sciences Ltd (2007–2012)
The table below shows the annual Asset Resilience Ratio data for StageZero Life Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2012-12-31 | 8.08% | $811.29K | $10.04 Million | -32.24pp |
| 2011-12-31 | 40.32% | $1.64 Million | $4.07 Million | +12.36pp |
| 2010-12-31 | 27.96% | $1.40 Million | $5.00 Million | +26.58pp |
| 2009-12-31 | 1.38% | $87.58K | $6.36 Million | -0.75pp |
| 2007-12-31 | 2.12% | $403.92K | $19.03 Million | -- |